These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15645681)

  • 1. Robustness studies on virus inactivation: definition of parameters and their generic use.
    Dichtelmüller H
    Dev Biol (Basel); 2004; 118():125-7. PubMed ID: 15645681
    [No Abstract]   [Full Text] [Related]  

  • 2. Methods for validation of hepatitis B virus inactivation.
    Gerlich WH; Glebe D
    Dev Biol (Basel); 2004; 118():113-22. PubMed ID: 15645680
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantitative NAT for pathogen inactivation verification.
    McKenney K; Gillmeister L; Marlowe K; Armistead D; Burgess W; Drohan W
    Dev Biol (Basel); 2004; 118():81-8. PubMed ID: 15645676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 5. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
    [No Abstract]   [Full Text] [Related]  

  • 6. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products.
    Unger U; Poelsler G; Modrof J; Kreil TR
    Transfusion; 2009 Sep; 49(9):1924-30. PubMed ID: 19453977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Virus inactivation in a single unit of plasma for transfusion].
    Zhiburt EB
    Med Tekh; 2008; (3):36-9. PubMed ID: 18688943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualification of virus/cell systems for their intended use.
    Gröner A
    Dev Biol (Basel); 2004; 118():55-63. PubMed ID: 15645673
    [No Abstract]   [Full Text] [Related]  

  • 9. UV-C treatment of protein solutions.
    Macleod AJ; Li Q; Bienek C; Foster PR
    Biologicals; 2007 Oct; 35(4):373. PubMed ID: 17254799
    [No Abstract]   [Full Text] [Related]  

  • 10. Virological issues in the use of cell therapies.
    Minor PD
    Dev Biol (Basel); 2004; 118():151-3. PubMed ID: 15645685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDA Virus Filter Task Force update.
    Sofer G
    Dev Biol (Basel); 2004; 118():129-31. PubMed ID: 15645682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H5N1 influenza virus and the safety of plasma products.
    Kreil TR; Unger U; Orth SM; Petutschnig G; Kistner O; Poelsler G; Berting A
    Transfusion; 2007 Mar; 47(3):452-9. PubMed ID: 17319825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An industry perspective on plasma-derived products.
    von Hoegen I
    Dev Biol (Basel); 2004; 118():31-5. PubMed ID: 15645670
    [No Abstract]   [Full Text] [Related]  

  • 14. Effective coronavirus reduction by various production steps during the manufacture of plasma-derived medicinal products.
    Schräder T; Koch J; Ross R; Schäfer W; Keiner B; Roth NJ; Widmer E
    Transfusion; 2020 Jun; 60(6):1334-1335. PubMed ID: 32542716
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sindbis virus as a tool for quality control of viral inactivation of heated and chemically treated plasma-derived products.
    Espíndola OM; Belluci MS; Oliveira BC; Liberto MI; Cabral MC
    J Virol Methods; 2006 Jun; 134(1-2):171-5. PubMed ID: 16507321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of dengue virus in the plasma-derived therapeutic proteins.
    Xie YW; Chan PK; Szeto CK; Kwok SY; Chu IM; Chu SS; Cheung JL; Wong SW; Ali MB; Wong BL
    Transfusion; 2008 Jul; 48(7):1342-7. PubMed ID: 18315529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
    Welch J; Bienek C; Gomperts E; Simmonds P
    Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
    Roberts PL
    Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.